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Abstract
Although screening for pre-cancerous cervical lesions and human papilloma virus (HPV)
vaccination are accepted and effective means to prevent cervical cancer, women in Mali
have limited access to these interventions. In addition, cervical cancer prevention by HPV
vaccination has been controversial in some settings. To reduce cervical cancer prevalence
and increase HPV vaccine uptake, it is important to understand the level of knowledge
about cervical cancer screening and practices related to vaccination in at-risk populations.
In this study, the level of knowledge about HPV and cervical cancer and attitudes towards
vaccination were assessed among 301 participants (male and female, adults and adoles-
cents) in a house-to-house survey in two urban neighborhoods in Bamako, Mali. The survey
was combined with a brief educational session on HPV. Prior to the education session, over-
all knowledge of HPV infection and cervical cancer was very low: only 8% knew that HPV is
a sexually transmitted infection (STI). Less than 20% of women had ever consulted a gyne-
cologist and less than 3% had ever had cervical cancer screening. After hearing a descrip-
tion of HPV vaccine, more than 80% would accept HPV vaccination; fathers and husbands
were identified as primary decisions makers and local clinics or the home as preferred sites
for vaccination. This study provides information on STI knowledge and vaccine acceptance
in Bamako, Mali in 2012, prior to the introduction of HPV vaccination.
Introduction
Nearly 85% of worldwide cervical cancer (CC) cases diagnosed each year occur in low-
resource countries. The main risk factor for CC is infection with high-risk types of human pap-
illomavirus (HPV) [1]. In high-resource countries, prevention programs such as vaccination
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against HPV or CC screening have decreased the rates of CC and improved patient outcomes
[2]. In contrast, the lack of access to early prevention measures such as gynecologic examina-
tion and cytology-screening programs, combined with a high incidence of HPV types 16 and
18 infection [3,4], contribute to the high prevalence of CC in some developing countries [5].
In West Africa, CC is the second most common and lethal cancer among women. A total of
27,300 new cases are identified in West Africa every year, and 16,500 deaths per year are attrib-
uted to CC [6]. High-risk HPV types 16 and 18 are found in 60% to 70% of invasive cervical
cancer (ICC) cases in Africa [7]. Mali, a West African country with an estimated population of
15 million (4.08 million women aged 15 and over), has the highest regional rate of CC, with an
age-standardized rate of 44.2 cases per 100,000 women [8,9]. The prevalence of high-risk HPV
types has been estimated at 12% among previously unscreened women aged 15–65 [10,11].
Previous studies conducted in Mali showed that high-risk HPV types 16 and 18 could be iden-
tified in 54% to 62% of CC cases [12,13]. Unfortunately, according to household surveys per-
formed by the WHO in 2000–2001, cervical cancer screening coverage is estimated at 4.8%
(women aged 18–69 years) [8].
As of 2015, HPV vaccines are only available through pilot programs in some regions of
Bamako prior to countrywide HPV vaccine introduction. At the time this study was performed
(2011–2013), HPV vaccine was not available, but plans were underway to bring the HPV vac-
cine to Mali. The GAVI alliance recently initiated a pilot program (2014–2016). This program
targeted 12,500 10-years old girls in Fana and Commune V of Bamako. The vaccination in-
cludes three injections administered at school or in health centers and through community
outreach. Scale up is planned for late 2016 or early 2017. In anticipation of the introduction of
HPV vaccination and the expansion of current CC screening programs in Mali, it is important
to assess the willingness of Malians to be vaccinated and the level of knowledge about the link
between HPV and CC. Recent studies have shown that one of the barriers to the delivery of
CC screening is the lack of awareness about the disease [14]. Education campaigns have been
shown to increase the level of acceptance of vaccines such as the polio vaccine [15]. Further-
more, HPV vaccination is currently recommended for adolescent girls aged 9–12 [16], for
whom autonomous decision-making is limited. Acceptance of vaccination is dependent on
many factors, such as individual knowledge, beliefs about susceptibility, perceptions of vaccine
effectiveness, family and physician perspectives, sexual and cultural practices, and anticipated
costs of vaccination [17]. We therefore assessed the knowledge, attitudes, and practices regard-
ing CC and HPV among teenagers and adults living in two urban regions of Bamako, Mèkin-
Sikoro and Djikoroni.
Methods
Recruitment of participants
Participants were recruited between May and June 2011 in Mèkin-Sikoro and Djikoroni, two
peri-urban communities of Bamako that have been site for previous population surveys by our
group [17]. Briefly, a team of four trained interviewers (one adolescent female, one adolescent
male, one adult female, and one adult male) approached members of households separately. In
Me´kin-Sikoro, the selection of households proceeded within the six districts in the neighbor-
hood as follows: the first interviewer approached the closest household to the central health
clinic, the second interviewer approached the next closest household, and so on. In Djikoroni,
households were selected in advance based on the age of the residents. According to the study
protocol, if at least one eligible participant matching the sex and age group of the interviewer
was present at the time of visit, the household was entered into the study. Adolescents were eli-
gible if aged 12–17 years and living in the household, and if a guardian was available to provide
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consent. Adults were eligible if aged18 years and living in the household. Participation in
the study was explained and proposed to the first eligible individual to interact with the age
and sex- matching interviewer within a household. A total of 301 participants (150 living in
households in Djikoroni, 151 living in Me´kin-Sikoro) agreed to participate in this study and
signed (or their guardian signed) an informed consent form.
Assessment of knowledge, attitudes and practices towards HPV and CC
and willingness to participate in an HPV vaccine trial
Two standardized questionnaires were used in the structured interviews. These questionnaires
were pilot-tested in March 2011 [17], and were adapted for relevancy to each sample subset.
Interviews were conducted in participants’ home. When a household was approached, the
interviewer engaged discussion with an age and gender- matched member of the household,
i.e. a younger (18–25 year old) female interviewer would interact with the adolescent female in
the household; older female interviewers were matched with older women, etc. Questions
were asked by the interviewers, who filled out the questionnaires. A guardian was present
when adolescents were interviewed. After the study purpose was explained and informed con-
sent obtained, the first questionnaire was submitted to the participants to assess knowledge,
attitudes and practices; vaccine acceptability; willingness to participate in an HPV vaccination
program; and vaccination decision-making capacity. The detailed questionnaire is available in
supporting information file 1 (S1 File). Demographic characteristics and information about
marital status and sexual experiences and behaviors were also collected. An information and
education session took place after the first interview, consisting of information about HPV
and CC, their symptoms and causes, and the availability of CC testing in Mali. After this edu-
cational session, a second questionnaire was administered to measure immediate information
retention and comprehension from the education session. The detailed questionnaire is avail-
able in supporting information file 2 (S2 File). The structured interviews were conducted in
Bambara, the main language in Mali, following a script that was provided to the interviewers
in French.
Statistical analysis
Individual results from the surveys was hand-entered into a spreadsheet and then collated into
summary tables (Microsoft Excel). All statistical analyses were performed using GraphPad
(http://www.graphpad.com). In order to evaluate the impact of the education session, we com-
pared answers before and after the education session with a McNemar test that tests the likeli-
hood of a change in binary response after an intervention to be random. p<0.01 was
considered significant.
Ethics statement
The protocol of this study and the surveys were reviewed and approved by the Committee of
Ethics of the Faculty of Medicine, Pharmacy and Odonto-stomatology in Bamako, Mali, and
by the Ethical and Independent Review Services Midwest Board, Independence, MO, United
States. The approved informed consent document was translated from French to Bambara, the
local language. The consent form was read aloud to individuals who were illiterate. All partici-
pants provided a signature or fingerprint indicating their informed consent. Written informed
consent was obtained from the next of kin, caretakers, or guardians on behalf of the minors/
children enrolled in the study. All interviewers were trained with information about HPV and
Cervical cancer and ethics considerations. Informed consent forms and training manual are
available in supporting information files 3 and 4 respectively (S3 and S4 Files).
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Results
Characteristics of the study participants
The characteristics of the participants are summarized in Table 1. Of the total eligible partici-
pants approached, 301 (100%) elected to participate in the structured interview. Half of the
households were located in Sikoro and the other half in Djikoroni, two densely inhabited and
low-income neighborhoods of Bamako. The majority of participants had attended some school
(n = 229; 76.1%). Male participants reported more sexual partners before marriage (average
7.8) than women (average 1.4). Of note, among those reporting having had sex 26 (of 176, or
14.7%) reported having been forced to have sex against their will (17.2% of females; 12.4% of
Table 1. Characteristics of the study participants.
Total (N = 301) Female (N = 149) Male (N = 152)
N % N % N %
Mean Age (SD) 22.0 (9.7) 21.6 (9.5) 22.3 (9.9)
Age (years) 12–17 146 48.5 74 49.7 72 47.4
18–26 84 27.9 39 26.1 45 29.6
>26 71 23.6 36 24.2 35 230
Circumcised/excised‡ 292 97.0 141 94.6 151 99.3
Ever attended school 229 76.1 103 69.1 126 82.9
Married 87 28.9 59 39.6 28 18.4
Adolescents (<18 years) 6 4.1 6 8.1 0 0.0
Adults (18 years) 81 52.3 53 70.7 28 35.0
Polygamous marriage* 11 12.6 10 17.0 1 3.6
Average number of wives† (SD) 2.0 (0.6) 2.0 (0.7) 2.0 (N/A)
Have had sexual intercourse 176 58.5 87 58.4 89 58.6
Mean age of sexual debut§ (SD) 17.4 (4.4) 16.5 (2.5) 18.4 (5.4)
Age of sexual debut§ (years) <15 30 17.0 17 19.5 13 14.6
15–18 82 46.6 47 54.0 39 39.3
>18 64 36.4 23 26.4 41 46.1
Mean number of sexual partners§ (SD) 3.0 (5.3) 1.6 (1.2) 4.3 (7.2)
Mean number of sexual partners before marriage# (SD) 4.0 (8.8) 1.4 (0.8) 7.8 (13.1)
Forced to have sex§ 26 14.7 15 17.2 11 12.4
Sex in exchange for money or gifts§ 14 8.0 6 6.9 8 9.0
Know what contraception is — 87 58.4 —
Use some form of contraception** — 37 42.5 —
Condoms †† — 3 8.1 —
Birth control pill †† — 15 40.5 —
Birth control injection †† — 9 24.3 —
Other †† — 11 29.7 —
Note: SD = standard deviation, N/A = Non-Applicable
‡ Excision refers to Type II female genital cutting, or the removal of the clitoris and inner labia.
* Among those who were married; N = 87 for total; N = 59 for female; N = 28 for male.
† Among those who were in a polygamous marriage; N = 11 for total; N = 10 for female; N = 1 for male.
§ Among those reporting having had sex; N = 176 for total; N = 87 for female; N = 89 for male.
# Among those who were married, reporting having had sex before marriage; N = 42 for total; N = 25 for female; N = 17 for male.
** Among those who knew what contraception is; N = 87.
†† Among those who use contraception; N = 37.
doi:10.1371/journal.pone.0171631.t001
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males). Fourteen individuals (8.0%; 6 females, 8 males) reported having had sex in exchange
for money or gifts.
Knowledge of STIs, HPV, and CC
Before the educational session, 194 participants (64.5%) reported they knew what a sexually
transmitted infection (STI) was (Fig 1A). Forty-six participants (15.3%) reported having a STI
in the past (data not shown), while 157 participants (52.2%) could correctly identify a method
of protection against STIs and only 144 (47.8%) could correctly identify a place where STI
exams were offered. Awareness about HPV was much lower: only 26 participants (8.6%) knew
that HPV was transmitted by sexual contact (Fig 1B). None of the female subjects were able to
correctly describe at least one symptom related to HPV. Only 21 participants (7%) correctly
stated that HPV was one of the major causes of CC (7 females, 14 males) prior to the educa-
tional session (Fig 1C). Overall, knowledge about STIs, HPV, and CC was better among males
than females. Adolescents demonstrated very poor knowledge: only 5 (3.4%) knew that HPV is
a STI.
The knowledge of the participants significantly increased after the education session. Nota-
bly, all participants who knew that HPV was a STI correctly said that HPV vaccination could
prevent CC (Fig 1C). On average, the number of participants who could correctly answer the
questions asked increased by 30% after the brief education session.
Access to gynecological care
Questions related to gynecological information were asked to female participants. Only 31
(20.8%) consulted with a provider for gynecological issues at least once (Table 2). Although
cervical cancer screening using visual inspection with acetic acid and Lugol’s iodine (VIA
and VILI) is available in Mali, very few women and adolescent girls knew what this test was
(N = 10, 6.7%), and only one-third (2.0% overall) reported that they had ever received such an
exam (Table 2). Only 41 women and 21 girls (54.7% and 28.4%, respectively) had heard of CC,
and 6 participants could name at least one CC symptom. Adult women were well aware of
what was CC screening but only 34 (22.8%) knew where to get screened before the educational
session (Fig 2).
Willingness to vaccinate against HPV and vaccination preferences
Vaccine acceptability was high among the participants. Nearly all participants had received a
vaccine before (N = 296; 98.3%, data not shown). A majority of participants (N = 290, 96.3%)
said they would like the HPV vaccine to be available in Mali and 233 (77.4%) said that they
would participate in a vaccine trial (Fig 3A). The education session increased the HPV vaccine
acceptance in all groups, especially among adolescents (from 75.3% to 91.8%, Fig 3A). Among
all groups, the preferred locations to receive the vaccine were community clinics (CSCOM)
and the participants’ homes (Fig 3B). Home visits (N = 149; 58.9%) were preferred over SMS
or phone calls (N = 99; 39.1%) for the purposes of receiving information about HPV vaccina-
tion appointments (Fig 3C).
Ability to autonomously decide to vaccinate
The ability to autonomously decide to vaccinate oneself or their child with an HPV vaccine
was significantly different across gender and age groups (Fig 4). Half of adult females (39,
52.0%) said they would have to ask their husband’s permission before deciding to vaccinate
their child. However, most adult men (88.9%) were not able to decide or would ask their
Knowledge, attitudes, practices related to HPV vaccination in Mali
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Fig 1. Knowledge of STIs, HPV, and CC. Participants were asked about STIs (A), HPV (B) and cervical
cancer (C) before and after a brief educational session. Percentages of participants able to answer the
question are reported in the graphs for all participants (Total, N = 301), female (N = 148), male (N = 152) and
adolescents (N = 146). * p<0.01 when compared to answers before the educational session (McNemar test).
Women reported much more extensive knowledge of STIs than HPV, and while a brief educational session
improved knowledge, more needs to be done.
doi:10.1371/journal.pone.0171631.g001
Knowledge, attitudes, practices related to HPV vaccination in Mali
PLOS ONE | DOI:10.1371/journal.pone.0171631 February 13, 2017 6 / 13
parent’s opinion. Only one adult male participant (1.3%) reported that he would consult his
wife about HPV vaccination. Among adolescents, boys would be more inclined to ask permis-
sion from their parents, but overall they would be more involved in the decision to get vacci-
nated (59.7%) than girls (43.2%).
Discussion
This study assessed knowledge towards HPV, CC, and HPV vaccination in a representative
sample of the community in two peri-urban neighborhoods of Bamako, Mali before the imple-
mentation of HPV vaccination and widespread availability of CC screening in the country. We
also assessed vaccination decision autonomy and preferred vaccination locations.
In a parallel study, our group recently demonstrated that the two high-risk HPV 16 and 18
types were found in most of the CC biopsies in a group of patients from a main hospital in
Bamako (manuscript submitted contemporaneously). Modeling studies have shown that
Table 2. Gynecological care knowledge and practices (female participants).
Total (N = 149) Women* Girls† (N = 74)
N (%) (N = 75) N (%) N (%)
Has been evaluated for gynecology problems 31 (20.8) 26 (34.7) 5 (6.8)
Knows what a CC screening is (VIA/VILI) 10 (6.7) 5 (6.7) 5 (6.8)
Has ever had a CC screening (VIA/VILI) 3 (2.0) 2 (2.7) 1 (1.4)
Has heard of CC 62 (41.6) 41 (54.7) 21 (28.4)
Knows at least one CC symptom 6 (4.0) 4 (5.3) 2 (2.7)
Knows that CC can cause death in women 93 (62.4) 68 (90.6) 25 (33.8)
* Includes female adults aged 18 years or older.
† Includes female adolescents aged 12–17 years.
doi:10.1371/journal.pone.0171631.t002
Fig 2. Knowledge about CC screening. Female participants (N = 149) were asked if they knew what CC
screening was and about access to CC screening in Mali. Results are presented before and after the
educational session for all female participants (Total, N = 149), female adults (Women, N = 75) and female
adolescents (Girls, N = 74). * p<0.01 and ** p<0.05 when compare to answers before the educational
session (McNemar test).
doi:10.1371/journal.pone.0171631.g002
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Fig 3. Willingness to be vaccinated against HPV and immunization preferences. A. Willingness to
participate in a vaccine trial and to get vaccinated was assessed before and after the educational session for
all participants (Total, N = 301), female (N = 149), male (N = 152) and adolescents (N = 146). * p<0.01 and **
p<0.05 when compare to answers before the educational session (McNemar test). B, C: The preferred
Knowledge, attitudes, practices related to HPV vaccination in Mali
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vaccination against HPV 16 and 18 by either of the currently available bi or quadri-valent
HPV vaccines could reduce the prevalence of HPV-associated CC in Mali by a rate directly
proportional to the coverage of the population. For example, 15% vaccination coverage would
reduce the maximum prevalence of infection from 39% to 33%, whereas 90% coverage would
reduce the peak prevalence of infection to 7% [18]. Based on available information on the
prevalence of HPV in Mali and the cost of vaccination, the introduction of HPV vaccine in
Mali would be cost-effective [11].
Among all subsets of the population engaged in this survey, knowledge of vaccination and
willingness to vaccinate themselves and/or their children against HPV was high. Most of the
participants would be willing to participate in a HPV vaccine trial. This was consistent with a
prior study conducted by our group, in which 279 individuals who were approached in market
places in Bamako Mali were surveyed about vaccine trial participation: 75% were willing to
location to get the vaccine and the preferred method of contact for booster was assessed among participants
who would choose to get vaccinated (Total, N = 253; Female, N = 113; Male, N = 140, Adolescents, N = 110).
Interest in vaccination was high, two locations were preferred (local clinics (CsCOMS) and at home), and
home visits rather than phone messages were preferred for reminders.
doi:10.1371/journal.pone.0171631.g003
Fig 4. HPV Vaccination Decision-making Autonomy. Participants were asked who would participate in the decision of
vaccinate their children (adults, A) or themselves (adolescents, B). Results are shown as percentage of female 18 years
(Women, N = 75), male 18 years (Men, N = 80), female <18 years (Girls, N = 74) and male <18 years (Boys, N = 72). *
“Other” includes participants who did not answer the question. Women reported less autonomy regarding vaccine
decision-making than men regarding vaccination for themselves and their children.
doi:10.1371/journal.pone.0171631.g004
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participate to a vaccine trial for tuberculosis, 70% for malaria, and 62% for human immunode-
ficiency virus (HIV) [unpublished results].
Most of the participants reported that they were 15–18 years of age at sexual debut, indicat-
ing that the current targets for HPV vaccination (girls aged 9–12 years [16]) would be appro-
priate in this setting. Indeed, since first sexual encounters seem to occur somewhat later
relative to developed countries, it may be possible to extend the target vaccination age higher
in Mali (to 15 years of age) than the range used elsewhere.
Sexual coercion and sexual violence, which put women at risk of HPV infection and other
STIs, appear to be common in this population. Overall, 14.7% of sexually active participants
reported having had forced sex (8.6% of all participants) at least once, including both females
and males. Self-reporting (in the participants’ home) may underestimate the true prevalence.
Studies in South Africa reported similar results, and surveys among young girls’ mothers
revealed that the risk of forced sex or sexual violence is a factor that positively influences their
willingness to vaccinate their child against HPV infection [19,20].
Our findings demonstrate that potential vaccination participants prefer to be contacted and
to receive vaccinations by home visits or at their local CSCOM (community clinic). This is
consistent with current practices in Mali, as vaccination campaigns are conducted at the com-
munity level, either in the CSCOM or in house-to-house campaigns for polio and measles
[21]. In these settings, parental permission to vaccinate girls against HPV could be obtained
during the clinic or home visits; in addition, methods to monitor vaccination completion at
the individual and neighborhood level, such as registries and databases, could be used [22].
Although high HPV vaccine coverage rates can be achieved through school-based delivery
strategies in adolescent girls (age 9–14) in low and middle-income countries [23], this strategy
poses a challenge for reaching those who do not attend school. Door-to-door vaccination cam-
paigns have been used as an effective strategy for delivering vaccines to hard-to-reach popula-
tions [24]. Prospective studies could be performed to compare clinic (CSCOM)-based,
household-based, and school-based vaccination in terms of coverage rates for the two to three
dose HPV vaccination that is currently recommended [16].
In this study, home visits were the preferred method of contact for participants. Phone calls
were preferred over text messages by all participants suggesting that contacting study partici-
pants through text reminders for second and third doses in a three-dose regimen may not
transfer to Mali at this time. This may be due to low literacy rates: only 31% of Malians over
age 15 are literate (2010 data from the WHO), meaning that 69% of the target population
would be unable to read a text message on a phone.
Another factor to be considered when designing a prevention program will be the autonomy
to make a health-related decision. This study is, to the best of our knowledge, is the first large-
scale study to examine the differences in permission required to receive HPV vaccination in
Mali. Female participants identified men (husbands and fathers) as the primary decision-makers
regarding HPV vaccination. Men had significantly greater autonomy in the decision to vaccinate
themselves than women and adolescents (p = 0.005). These findings were somewhat expected, as
Mali has a patriarchal decision-making structure [25]. Our results suggest that men’s opinions
will be an important factor to consider when implementing vaccination campaigns.
Although 52% of women need the approval of their husband to vaccinate their child, most
men would ask their parents or could not answer. Engagement of husbands has been shown to
be a critical factor for the delivery of CC screening in Malawi [14]. Therefore, involving men
in education about prevention programs, engaging men in making positive health decisions
for women and children, and including men in publicity materials will be important to pro-
mote prevention programs not only in Mali, but also in other societies where men are heavily
involved in decisions about women’s health.
Knowledge, attitudes, practices related to HPV vaccination in Mali
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Critical issues that remain to be addressed to improve the situation regarding CC preva-
lence and limited access to CC screening in Mali and West Africa include the following: (1)
low levels of HPV and CC knowledge; (2) limited knowledge about the purpose and location
of cervical cancer screening, and (3) lack of access to cervical cancer screening. We are cur-
rently evaluating methods for increasing participation in HPV/CC screening using community
education sessions and a patterned cloth as a visual teaching tool.
It is clear from this study that HPV vaccination campaigns should be carefully structured,
taking into consideration local cultural norms. Autonomy regarding vaccination was low
among women and girls, thus, future studies should examine whether HPV vaccination cam-
paigns should be conducted in clinical settings or at home, and how decisions about HPV vac-
cination, that are made in consultation with fathers or husbands, could be facilitated.
In conclusion, this study provides information to guide future interventions such as HPV
vaccination, CC screening campaigns, and publicity campaigns designed to improve HPV
knowledge and vaccine acceptability in West Africa. Our results may be useful to support the
implementation of vaccines against HPV in Mali. Implementation of HPV vaccination in Mali
(and West Africa) would avert tens of thousands of future deaths. Perhaps most important,
HPV vaccination is desired and would be accepted by the vast majority of participants in this
study.
Supporting information
S1 File. Questionnaire before education session (English). Questions asked before the educa-
tion session are listed in S1 file. Every participant was asked questions 1–10, 21–31 and 41–50.
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